Result for
Topic: Testing and Treatment
March 3, 2021
Comparative Performance of SARS-CoV-2 Lateral Flow Antigen Tests Demonstrates Their Utility for High Sensitivity Detection of Infectious Virus in Clinical Specimens
[Pre-print, not peer-reviewed] A comparison of six commercial rapid antigen lateral flow devices (LFDs) using combined nasal/oropharyngeal swabs obtained from clinical specimens demonstrated sensitivities ranging from 65% to 89%. Sensitivity increased in most tests to over 90% for samples with cycle threshold (Cts) lower than 25 (higher viral concentrations) and most had a high specificity…
March 2, 2021
A Shorter Symptom-Onset to Remdesivir Treatment (SORT) Interval Is Associated with a Lower Mortality in Moderate-to-Severe COVID-19: A Real-World Analysis
In a retrospective analysis of patients with moderate-to-severe COVID-19 in India (n=346), patients receiving remdesivir 9 days or less after symptom onset had significantly lower all-cause mortality compared to those who received it after 9 days (18% vs 34%). Odds of death were reduced by 37% among patients receiving remdesivir <=9 days post-symptom onset compared…
March 1, 2021
Association of Convalescent Plasma Treatment With Clinical Outcomes in Patients With COVID-19
A meta-analysis of randomized clinical trials comparing patients with COVID-19 treated with convalescent plasma versus control did not detect any significant differences in all-cause mortality, length of hospital stay, mechanical ventilation use, clinical improvement, or clinical deterioration. Results from 4 published, peer-reviewed RCTs including 1,060 patients indicated that the risk ratio for mortality was 0.93….
Antibodies with Potent and Broad Neutralizing Activity against Antigenically Diverse and Highly Transmissible SARS-CoV-2 Variants
[Pre-print, not peer-reviewed] A study identifying the structural and functional determinants of serum with broad neutralization of SARS-CoV-2 determined that combinations of two antibodies with broadly neutralizing activity decrease the in vitro generation of escape mutants. The structural characteristics of four monoclonal receptor-binding domain-targeting antibodies isolated from three early-outbreak convalescent donors with broadly neutralizing polyclonal…
February 26, 2021
The Effects of “Dry Swab” Incubation on SARS-CoV-2 Molecular Testing
Parikh et al. suggest that “dry swabs” (which do not use transport medium) may be accurate for SARS-CoV-2 diagnostics. Flocked swabs were inoculated with SARS-CoV-2 and then incubated in either the typical medium or a dry, sterile conical tube. All dry swabs tested at days 1, 2, and 7 provided results that were within two…
An Updated Systematic Review and Network Meta-Analysis of 25 Randomized Trials Assessing the Efficacy and Safety of Treatments in COVID-19 Disease
A systematic review and meta-analysis of randomized trials published between the beginning of the pandemic and September 2020 found that ten days of remdesivir compared to standard care was associated with a lower risk of death in patients with COVID-19. The review, which covered 25 trials evaluating 17 treatments among a total of 11,597 patients,…
Dexamethasone in Hospitalized Patients with Covid-19 — Preliminary Report
In patients hospitalized with COVID-19, the administration of 6 mg/day for ten days of the steroid dexamethasone resulted in statistically significantly lower 28-day mortality among those who were receiving either invasive mechanical ventilation (29% vs. 41%) or oxygen alone (23% vs. 26%) at randomization but not among those receiving no respiratory support (18% vs. 14%)….
Bamlanivimab Does Not Neutralize Two SARS-CoV-2 Variants Carrying E484K in Vitro
[Pre-print, not peer-reviewed] An in vitro study of the neutralizing ability of the monoclonal antibody treatment bamlanivimab against five emerging SARS-CoV-2 variants of concern determined no neutralization effect could be detected against either the B.1.351 (first described in South Africa) or P.2 (first described in Brazil) variants, both of which harbor the E484K substitution. The…
Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19
A trial of two IL-6 receptor antagonists, tocilizumab and sarilumab, in critically ill hospitalized adults with confirmed COVID-19 found that in-hospital mortality in the pooled IL-6 receptor antagonist groups was 27% (108 of 395 patients), as compared with 36% (142 of 397 patients) in the group of people receiving standard care, which results in a…
Tocilizumab in Hospitalized Patients with Severe Covid-19 Pneumonia
A multi-center phase 3 clinical trial of intravenous treatment using the IL-6 receptor antagonists tocilizumab in hospitalized patients with severe COVID-19 pneumonia found that tocilizumab did not result in significantly better clinical status or reduced mortality compared to placebo (19.7% vs 19.4%) at 28 days. At day 14, clinical status was also not to be…
Previous page Next page